Chronic Liver Disease
Ursodeoxycholic acid doesn't resolve nonalcoholic steatohepatitis
Published in Hepatitis Weekly, May 24th, 2004
According to recent research published in the journal Hepatology, "no effective medical therapy is available for all patients with nonalcoholic steatohepatitis (NASH). Ursodeoxycholic acid (UDCA) has been suggested to be of benefit based on open label clinical studies. We randomized 166 patients with liver biopsy proven NASH to receive between 13 and 15 mg/kg/d of UDCA or placebo for 2 years."
"End points included changes in liver test results and liver histology at 2 years of therapy. The treatment groups were comparable at entry with regard to age, gender, risk factors for...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-05-24)
More Articles from Hepatitis Weekly
- Chronic Liver Disease
Iron burden is not a fibrosis precursor in nonalcoholic fatty liver disease - Hepatology
Peginterferon alfa-2a reduces fibrosis in chronic hepatitis C patients - Liver Transplantation
Viral response endures in transplant recipients treated for recurrent HCV - Mutagenesis
Hepatitis C virus uses hit-and-run mechanisms to boost cancer formation - Addiction Medicine
Occult hepatitis B virus infections reign among Baltimore injection drug users - Alcoholism
Liver transplantation is the sole option for many with alcoholic liver disease - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
